Hypertension, Pulmonary Clinical Trial
Official title:
Effect of Exercise Training in Arterial and Chronic Thromboembolic Pulmonary Hypertension in Switzerland and Standardization With European Countries
Pulmonary Hypertension (PH) is a serious disease with a dismal prognosis when left untreated. Advances in medical therapy have improved survival according to recent registries and systematic reviews, but are associated with high healthcare costs. Earlier studies in Heidelberg, Germany showed good evidence for the effect of exercise training on improving exercise performance, quality of life and pulmonary hemodynamics in patients with pulmonary hypertension. The main objectives of the present project are: 1. to investigate the quality of the implementation of a standardized 3 week in-hospital exercise training program on markers of outcome and disease severity in PH-patients in Switzerland immediately after training and after 3 and 12 month. 2. to look whether training with hyperoxia vs. standard care might be more effective. This is a multicentre, randomized parallel-group trial where the intervention rehabilitation is delayed in one group so that they can serve as standard care controls for the others. In a nested single-centre randomized-controlled trial patent will additionally be randomized to receive either usual rehabilitation (UR) or rehabilitation with standardized supplemental oxygen therapy (SSOT) during nights and ergometer training. Patients will receive a PH specific rehabilitation program during 3 weeks followed by an instructed home-based training program for 12 weeks. Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights upon written informed consent.
Status | Recruiting |
Enrollment | 32 |
Est. completion date | December 2023 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - WHO functional class II-IV - PH diagnosed by right heart catheter showing: - Baseline mean pulmonary arterial pressure (mPAP) = 25 mmHg - Baseline pulmonary vascular resistance (PVR) > 240 dyn x s x cm-5 - Baseline pulmonary capillary wedge pressure (PCWP) = 15 mm Hg - Patients receiving maximal PH therapy including intensified treatment with diuretics and who have been stable for 2 months before entering the study - PH target therapy should not be expected to change during the entire 15-week study period - Negative pregnancy test (ß-HCG) at the start of the trial - Able to understand and willing to sign the Informed Consent Form Exclusion Criteria: - PH due to significant left heart disease (Wedge = 15mmHg) or lung disease (FEV1 = 60% predicted) - Pregnancy at study onset - Walking disability - Any change in disease-targeted therapy within the last 2 months - Any subject who is scheduled to receive another investigational drug during the course of this study - Any other relevant concomitant disease - Systolic blood pressure < 85 mmHg - History or suspicion of inability to cooperate adequately |
Country | Name | City | State |
---|---|---|---|
Switzerland | UniversityHospital Zurich, Department of Pulmonology | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Hospitalisation days | Baseline, 3 weeks, 15 weeks, 6 and 12 months | ||
Primary | 6 Minute walking test | Change from Baseline to 15 weeks | ||
Primary | Constant cardiopulmonary exercise testing change in endurance time | Change from Baseline to 15 weeks | ||
Secondary | Quality of Life (questionnaire) | Minnesota living with heart failure questionnaire, Camphor, short form 36 item | Baseline, 3 weeks, 15 weeks, 6 and 12 months | |
Secondary | Sit-to-Stand (physiological parameter) | Number of Sit-to-Stand performed in 1 minute | Baseline, 3 weeks, 15 weeks, 6 and 12 months | |
Secondary | Stair Ascent (physiological parameter) | Force, Power and Time needed to climb 5 steps | Baseline, 3 weeks, 15 weeks, 6 and 12 months | |
Secondary | Cognitive function (questionnaire) | Trail Making Test A & B, Stroop 1-3, 5 point test | Baseline, 3 weeks, 15 weeks, 6 and 12 months | |
Secondary | Hemodynamic (physiological parameter) | Pulmonary artery pressure, cardiac output | Baseline, 3 weeks, 15 weeks, 6 and 12 months | |
Secondary | Functional class (scale) | Baseline, 3 weeks, 15 weeks, 6 and 12 months | ||
Secondary | Lung function (physiological parameter) | Forced vital capacity and liters in 1 second, Total lung capacity, diffusion of carbon dioxide | Baseline, 3 weeks, 15 weeks, 6 and 12 months | |
Secondary | Daily activity (energy expenditure, steps per day, sleep time and efficiency, lying down time, physical activity level, metabolic equivalent units) | Actigraphy | Baseline, 3 weeks, 15 weeks, 6 and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04095286 -
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
|
Phase 1 | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT02191137 -
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
|
Phase 4 | |
Completed |
NCT01959828 -
Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery
|
Phase 3 | |
Withdrawn |
NCT01202045 -
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
|
N/A | |
Completed |
NCT00963027 -
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
Completed |
NCT00963001 -
Effect of Food on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
Completed |
NCT01121458 -
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed
|
Phase 4 | |
Terminated |
NCT00825266 -
Insulin Resistance in Pulmonary Arterial Hypertension
|
Phase 4 | |
Terminated |
NCT00384865 -
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
|
Phase 2 | |
Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
Completed |
NCT02826252 -
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
|
N/A | |
Completed |
NCT02545465 -
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
|
N/A | |
Recruiting |
NCT04498299 -
Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
|
||
Active, not recruiting |
NCT02562235 -
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 | |
Completed |
NCT02755298 -
Chronic Clinical Effect of Acetazolamide
|
Phase 2/Phase 3 | |
Terminated |
NCT03043976 -
Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension
|
N/A | |
Completed |
NCT02576002 -
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
|
N/A | |
Completed |
NCT01317134 -
Endothelial Function in Patients With Pulmonary Arterial Hypertension
|
N/A | |
Completed |
NCT01178073 -
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 |